StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.26+0.02 (+0.28%)

Close on Nov 18, 2026Market cap $479.26MP/E –Yield –

Regenxbio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Regenxbio's revenue for the twelve months ending Jun 30, 2026 was $174.48M, up 12.0% year over year. For fiscal 2025 it was $170.44M, up 104.5% from the year before. Over ten years it grew 36.5% a year on average. The highest annual figure on record is $470.35M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$170.44M+104.5%
FY2024Dec 31, 2024$83.33M-7.7%
FY2023Dec 31, 2023$90.24M-19.9%
FY2022Dec 31, 2022$112.72M-76.0%
FY2021Dec 31, 2021$470.35M+204.3%
FY2020Dec 31, 2020$154.57M+338.7%
FY2019Dec 31, 2019$35.23M-83.9%
FY2018Dec 31, 2018$218.51M+2002.4%
FY2017Dec 31, 2017$10.39M+126.5%
FY2016Dec 31, 2016$4.59M-39.5%
FY2015Dec 31, 2015$7.59M+24.0%
FY2014Dec 31, 2014$6.12M+0.5%
FY2013Dec 31, 2013$6.09M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$108.02M+405.7%
Q1 FY2026Mar 31, 2026$6.39M-92.8%
Q4 FY2025Dec 31, 2025$30.34M+43.0%
Q3 FY2025Sep 30, 2025$29.73M+22.9%
Q2 FY2025Jun 30, 2025$21.36M-4.2%
Q1 FY2025Mar 31, 2025$89.01M+469.8%
Q4 FY2024Dec 31, 2024$21.21M-4.5%
Q3 FY2024Sep 30, 2024$24.20M-16.3%
Q2 FY2024Jun 30, 2024$22.30M+11.6%
Q1 FY2024Mar 31, 2024$15.62M-18.4%
Q4 FY2023Dec 31, 2023$22.21M-29.1%
Q3 FY2023Sep 30, 2023$28.91M+9.1%
Q2 FY2023Jun 30, 2023$19.98M-38.8%
Q1 FY2023Mar 31, 2023$19.14M-13.9%
Q4 FY2022Dec 31, 2022$31.35M-92.1%
Q3 FY2022Sep 30, 2022$26.51M-13.8%
Q2 FY2022Jun 30, 2022$32.65M+48.2%
Q1 FY2022Mar 31, 2022$22.22M+17.7%
Q4 FY2021Dec 31, 2021$398.66M+1759.0%
Q3 FY2021Sep 30, 2021$30.77M-68.9%
Q2 FY2021Jun 30, 2021$22.04M+33.0%
Q1 FY2021Mar 31, 2021$18.88M+7.0%
Q4 FY2020Dec 31, 2020$21.45M+82.2%
Q3 FY2020Sep 30, 2020$98.91M+572.9%
Q2 FY2020Jun 30, 2020$16.57M+110.2%
Q1 FY2020Mar 31, 2020$17.64M+1895.9%
Q4 FY2019Dec 31, 2019$11.77M-71.1%
Q3 FY2019Sep 30, 2019$14.70M+177.0%
Q2 FY2019Jun 30, 2019$7.88M-80.3%
Q1 FY2019Mar 31, 2019$884.00K-99.3%
Q4 FY2018Dec 31, 2018$40.78M+1898.9%
Q3 FY2018Sep 30, 2018$5.31M+297.2%
Q2 FY2018Jun 30, 2018$40.03M+510.0%
Q1 FY2018Mar 31, 2018$132.39M+28996.9%
Q4 FY2017Dec 31, 2017$2.04M+20.3%
Q3 FY2017Sep 30, 2017$1.34M+968.8%
Q2 FY2017Jun 30, 2017$6.56M–
Q1 FY2017Mar 31, 2017$455.00K–
Q4 FY2016Dec 31, 2016$1.70M–
Q3 FY2016Sep 30, 2016$125.00K–

More Regenxbio figures

See a number that looks wrong?